Heart aging represents one of the most consequential challenges facing an increasingly long-lived population, as cardiac decline directly limits both lifespan and healthspan quality. Traditional anti-aging interventions like senolytic drugs show promise but remain insufficient for comprehensive cardiac protection, creating urgent demand for novel therapeutic approaches.
This comprehensive review identifies PANoptosis—a recently discovered integrated cell death mechanism—as a central driver of cardiac deterioration. Unlike traditional apoptosis pathways, PANoptosis simultaneously activates multiple death programs including apoptosis, necroptosis, and pyroptosis, creating a more destructive cascade. The pathway accelerates cardiomyocyte loss while promoting tissue fibrosis and sustained inflammatory responses that progressively weaken heart function. Researchers have identified specific regulatory networks governing PANoptosis activation in cardiac tissue, revealing potential intervention points.
The therapeutic implications extend beyond current senescence-focused strategies. Gene editing approaches targeting PANoptosis regulators, RNA interference techniques, and novel drug delivery systems specifically designed for cardiac tissue represent promising preclinical directions. Combination therapies that simultaneously modulate multiple PANoptosis components may prove more effective than single-target approaches.
This mechanistic understanding positions PANoptosis research at the forefront of cardiac longevity science. While senolytics address aged cell accumulation, PANoptosis interventions could prevent the destructive cell death cascades that fundamentally drive heart aging. The pathway's integration of multiple death mechanisms suggests that successful targeting could yield more comprehensive cardiac protection than previous approaches, potentially extending both cardiac healthspan and overall longevity in aging populations.
